Literature DB >> 7494341

Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2.

S K Srinivas1, J W Sixbey.   

Abstract

In experimental B-cell infections, Epstein-Barr virus induced sustained expression of V(D)J recombinase-activating genes RAG1 and RAG2, whose aberrant activity has been implicated in chromosomal translocations in B-cell neoplasms. In cell lines in which RAG1 and RAG2 were detected, virus integrated into cellular DNA rather than assumed the configuration of extrachromosomal episomes. Expression of the Epstein-Barr virus nuclear antigen 1 in transient transfection assays was sufficient to induce both recombinase-activating genes.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7494341      PMCID： PMC189773     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  42 in total

1.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

2.  RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination.

Authors:  M A Oettinger; D G Schatz; C Gorka; D Baltimore
Journal:  Science       Date:  1990-06-22       Impact factor: 47.728

3.  Defective viral DNA in Epstein-Barr virus-associated oral hairy leukoplakia.

Authors:  D F Patton; P Shirley; N Raab-Traub; L Resnick; J W Sixbey
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

4.  The V(D)J recombination activating gene, RAG-1.

Authors:  D G Schatz; M A Oettinger; D Baltimore
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

5.  Interlocus V-J recombination measures genomic instability in agriculture workers at risk for lymphoid malignancies.

Authors:  S Lipkowitz; V F Garry; I R Kirsch
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

6.  When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates.

Authors:  E A Hurley; S Agger; J A McNeil; J B Lawrence; A Calendar; G Lenoir; D A Thorley-Lawson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia.

Authors:  J Limpens; D de Jong; J H van Krieken; C G Price; B D Young; G J van Ommen; P M Kluin
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

8.  A transformation-incompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection.

Authors:  J W Sixbey; P Shirley; M Sloas; N Raab-Traub; V Israele
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

9.  Selective expression of RAG-2 in chicken B cells undergoing immunoglobulin gene conversion.

Authors:  L M Carlson; M A Oettinger; D G Schatz; E L Masteller; E A Hurley; W T McCormack; D Baltimore; C B Thompson
Journal:  Cell       Date:  1991-01-11       Impact factor: 41.582

10.  Expression of human recombination activating genes (RAG1 and RAG2) in neoplastic lymphoid cells: correlation with cell differentiation and antigen receptor expression.

Authors:  J C Bories; J M Cayuela; P Loiseau; F Sigaux
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113
View more
  18 in total

1.  Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth.

Authors:  M S Kang; S C Hung; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

2.  Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1.

Authors:  Hong Wu; Priya Kapoor; Lori Frappier
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes.

Authors:  S Huang; D Stupack; P Mathias; Y Wang; G Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  Is the Epstein-Barr virus EBNA-1 protein an oncogen?

Authors:  Thomas F Schulz; Susann Cordes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

5.  Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428.

Authors:  D Kube; M Vockerodt; O Weber; K Hell; J Wolf; B Haier; F A Grässer; N Müller-Lantzsch; E Kieff; V Diehl; H Tesch
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 6.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

7.  c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1.

Authors:  A Polack; K Hörtnagel; A Pajic; B Christoph; B Baier; M Falk; J Mautner; C Geltinger; G W Bornkamm; B Kempkes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Rhesus lymphocryptovirus type 1-associated B-cell nasal lymphoma in SIV-infected rhesus macaques.

Authors:  A K Marr-Belvin; A K Carville; M A Fahey; K Boisvert; S A Klumpp; M Ohashi; F Wang; S P O'Neil; S V Westmoreland
Journal:  Vet Pathol       Date:  2008-11       Impact factor: 2.221

9.  The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold.

Authors:  Sibille Humme; Gilbert Reisbach; Regina Feederle; Henri-Jacques Delecluse; Kristine Bousset; Wolfgang Hammerschmidt; Aloys Schepers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

10.  Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation.

Authors:  Robert Valentine; Christopher W Dawson; Chunfang Hu; Khilan M Shah; Thomas J Owen; Kathryn L Date; Sonia P Maia; Jianyong Shao; John R Arrand; Lawrence S Young; John D O'Neil
Journal:  Mol Cancer       Date:  2010-01-05       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.